|
Chapter
4: Allergies
ALLERGIES:
_______________________________________________
I.
Significance
A.
A history of an allergy to a
vital drug could be a death
sentence.
B.
The major allergies
encountered in burn care are to b-lactam
antibiotics and sulfa drugs.
II.
History
A.
Patients stating any
allergic history must be taken
seriously
and penicillin should be held pending further investigations.
B.
An accurate history
of the specific reaction elicited is
important.
C.
You need to
distinguish between:
1. A true
allergic reaction which is anaphylaxis (i.e. hypotension,
laryngeal edema, bronchospasm) and cutaneous reactions
2. Nonspecific
symptoms (i.e. headache, nausea, emesis).
III.
Penicillin allergy
A.
Penicillin allergy is the most prevalent
immunological drug reaction in clinical medicine. IgE
antibodies directed against the b-lactam
ring are responsible for the type 1 reaction seen.
If a patient gives a history of an urticarial rash and
bronchospasm the diagnosis of penicillin allergy is made.
Though penicillin allergies are often diagnosed in childhood,
studies of this age group show that over-diagnosis of
penicillin allergy may occur in up to 94% of cases.[i]
Penicillin is regarded as the most important
antimicrobial agent in greatly reducing hemolytic
streptococcal and clostridial infections, and is often used to
treat burn cellulitis.
B.
Can we use cephalosporins?
1.
The overall incidence of adverse reactions from
cephalosporins ranges from 1% to 10%, with rare anaphylaxis
(< 0.02%). Post-marketing studies of second and third
generation cephalosporins showed no increase in allergic
reactions in patients with a history of penicillin allergy.
Similarly, patients with cephalosporin allergies have a
very small risk of penicillin reactions.
2.
A patient who states he or she has a history of
rash to penicillin can be treated instead with a first
generation cephalosporin.
Patients with anaphylactic reactions to penicillin
should receive neither penicillin nor cephalosporin.
These patients can be treated with vancomycin and
penicillin desensitization in conjunction with recommendations
by an infectious disease specialist. Intravenous
desensitization is a rapid, safe, and effective technique for
patients demonstrating hypersensitivity to beta-lactam
antibiotics who require therapy with these medications.[ii],[iii]
3.
Penicillin skin tests are not used, as they do not
predict the likelihood of allergic reactions to cephalosporins
in patients with histories of penicillin allergy. [iv]
4.
RAST is a solid-phase sandwich radioimmunoassay to
detect allergen-specific IgE antibodies.
The AlaSTAT test is an enzymoimmunoassay alternative to
the RAST that is more rapid.
Neither of these is commonly used in confirming drug
allergies.
C.
Sulfa allergies
Allergies
to silver sulfadiazine and mafenide acetate, the two topical
agents used most widely in burn therapy today, have been
reported.[v],[vi],[vii],[viii],[ix]
The reactions are usually mild.
Serious hypersensitivity to these agents has been
rarely described.[x],[xi]
Only 2 to 5 percent of patients treated with
silvadine cream exhibit a minor maculopapular rash that rarely
requires discontinuation of the agent, and 5 to 50 percent of
patients treated with mafenide acetate develop a rash that is
easily controlled with antihistamines and also does not
require discontinuation.9,10,11
[i] Graff-Lonnevig V, et al,
Penicillin allergy -
A rare pediatric condition?
Arch Dis Child 1988;63:
1342-6.
[ii] Borish L. Tamir R.
Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. Journal
of Allergy & Clinical Immunology. 80(3 Pt 1):314-9,
1987 Sep.
[iii] Stark BJ. Earl HS. Gross
GN. Lumry WR. Goodman EL. Sullivan TJ. Acute and chronic desensitization
of penicillin-allergic
patients using oral penicillin.
Journal of Allergy
& Clinical Immunology. 79(3):523-32, 1987 Mar.
[iv] Anne S, Reisman RE. Risk
of administering cephalosporin antibiotics to patients
with histories of penicillin allergy. Ann Allergy Asthma
Immunol 1995; 74: 167-70.
[v] Dodd D, Stutman HR.
Current issues in burn wound infections.
Adv Pediatr Infect Dis 1991; 6:137-162.
[vi] Hoffman S.
Silver sulfadiazine:
an antibacterial agent for topical use in burns.
Scand J Plast Reconstr Surg 1984;18:119-126.
[vii] Monafo WW, Freedman B.
Topical therapy for burns.
Surg Clin North Am 1987;67:133-145.
[viii] Monafo WW, West MA.
Current treatment recommendations for topical burn
therapy. Drugs
1990; 40:364-373.
[ix] Taddonio TE, Thompson PD,
Smith DJ, Prasad JK.
A survey of wound monitoring and topical
antimicrobial therapy practices in the treatment of burn
injury. J
Burn Care Rehabil 1990;11:423-427.
[x] McKenna DR, Latenser LM,
Jones LM, Barrette RR, Sherman HF, Varcelotti JR.
Serious silver sulphadiazine and mafenide acetate
dermatitis. Burns
21(4):310-2, 1995 Jun.
[xi] Fraser-Moodie A.
Sensitivity to silver in a patient treated with
silver sulphadiazine (Flamazine).
Burns 18(1):74-5, 1992 Feb.
|